Artículo
Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
Autor/es | Murcia Casas, Belén
Carrillo Linares, Juan Luis Baquero Aranda, Isabel Rioja Villodres, José Merino Bohórquez, Vicente González Jiménez, Andrés Rico Corral, Miguel Ángel Valdivielso, Pedro |
Departamento | Universidad de Sevilla. Departamento de Farmacología Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2023-03-03 |
Fecha de depósito | 2024-04-05 |
Publicado en |
|
Resumen | Pseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate
(PPi) and a high activity of tissue-nonspecific alkaline phosphatase (TNAP). Lansoprazole is a partial
inhibitor of TNAP. The aim ... Pseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate (PPi) and a high activity of tissue-nonspecific alkaline phosphatase (TNAP). Lansoprazole is a partial inhibitor of TNAP. The aim was to investigate whether lansoprazole increases plasma PPi levels in subjects with PXE.We conducted a 2 2 randomized, double-blind, placebo-controlled crossover trial in patients with PXE. Patients were allocated 30 mg/day of lansoprazole or a placebo in two sequences of 8 weeks. The primary outcome was the differences in plasma PPi levels between the placebo and lansoprazole phases. 29 patients were included in the study. There were eight drop-outs due to the pandemic lockdown after the first visit and one due to gastric intolerance, so twenty patients completed the trial. A generalized linear mixed model was used to evaluate the effect of lansoprazole. Overall, lansoprazole increased plasma PPi levels from 0.34 0.10 M to 0.41 0.16 M (p = 0.0302), with no statistically significant changes in TNAP activity. There were no important adverse events. 30 mg/day of lansoprazole was able to significantly increase plasma PPi in patients with PXE; despite this, the study should be replicated with a large number of participants in a multicenter trial, with a clinical end point as the primary outcome. |
Agencias financiadoras | Asociación Española de Afectados por PXE |
Cita | Murcia Casas, B., Carrillo Linares, J.L., Baquero Aranda, I., Rioja Villodres, J., Merino Bohórquez, V., González Jiménez, A.,...,Valdivielso, P. (2023). Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial. International Journal of Molecular Sciences, 24 (5), 4899. https://doi.org/10.3390/ijms24054899. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
ijms-24-04899.pdf | 898.5Kb | [PDF] | Ver/ | |